Mohamad Alkhouli1, Fahad Alqahtani2, Muhammed Alhajji2, Chalak O Berzingi2, M Rizwan Sohail3. 1. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN. Electronic address: Mohamad.Alkhouli@wvumedicine.org. 2. Division of Cardiology, Department of Medicine, West Virginia University, Morgantown. 3. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: To assess contemporary trends in the incidence, characteristics, and outcomes of hospital admissions for infective endocarditis (IE) in the United States. PATIENTS AND METHODS: Patients ≥18 years admitted with IE between January 1, 2003, and December 31, 2016, were identified in the National Inpatient Sample. We assessed the annual incidence, clinical characteristics, morbidity, mortality, and cost of IE-related hospitalizations. RESULTS: The incidence of IE-related hospitalizations increased from 34,488 (15.9; 95% confidence interval [CI], 15.73, 16.06) per 100,000 adults) in 2003 to 54,405 (21.8; 95% CI, 21.60-21.97) per 100,000 adults) in 2016 (P<.001). The prevalence of patients below 30 years of age, and those who inject drugs, increased from 7.3% to 14.5% and from 4.8% to 15.1%, respectively (P<.001). The annual volume of valve surgery for IE increased from 4049 in 2003 to 6460 in 2016 (P<.001), but the ratio of valve surgery to IE-hospitalizations did not decrease (11.7% in 2003; 11.8% in 2016). There was also a temporal increase in risk-adjusted rates of stroke (8.0% to 13.2%), septic shock (5.4% to 16.3%), and mechanical ventilation (7.7% to 16.5%; P<.001). However, risk-adjusted mortality decreased from 14.4% to 9.8% (P<.001). Median length-of-stay and mean inflation-adjusted cost decreased from 11 to 10 days and from $45,810±$61,787 to $43,020±$55,244, respectively, (P<.001). Nonetheless, the expenditure on IE hospitalizations increased ($1.58 billion in 2003 to $2.34 billion in 2016; P<.001). CONCLUSIONS: There is a substantial recent rise in endocarditis hospitalizations in the United States. Although the adjusted in-hospital mortality of endocarditis and the cost of admission decreased over time, the overall expenditure on in-hospital care for endocarditis increased.
OBJECTIVE: To assess contemporary trends in the incidence, characteristics, and outcomes of hospital admissions for infective endocarditis (IE) in the United States. PATIENTS AND METHODS: Patients ≥18 years admitted with IE between January 1, 2003, and December 31, 2016, were identified in the National Inpatient Sample. We assessed the annual incidence, clinical characteristics, morbidity, mortality, and cost of IE-related hospitalizations. RESULTS: The incidence of IE-related hospitalizations increased from 34,488 (15.9; 95% confidence interval [CI], 15.73, 16.06) per 100,000 adults) in 2003 to 54,405 (21.8; 95% CI, 21.60-21.97) per 100,000 adults) in 2016 (P<.001). The prevalence of patients below 30 years of age, and those who inject drugs, increased from 7.3% to 14.5% and from 4.8% to 15.1%, respectively (P<.001). The annual volume of valve surgery for IE increased from 4049 in 2003 to 6460 in 2016 (P<.001), but the ratio of valve surgery to IE-hospitalizations did not decrease (11.7% in 2003; 11.8% in 2016). There was also a temporal increase in risk-adjusted rates of stroke (8.0% to 13.2%), septic shock (5.4% to 16.3%), and mechanical ventilation (7.7% to 16.5%; P<.001). However, risk-adjusted mortality decreased from 14.4% to 9.8% (P<.001). Median length-of-stay and mean inflation-adjusted cost decreased from 11 to 10 days and from $45,810±$61,787 to $43,020±$55,244, respectively, (P<.001). Nonetheless, the expenditure on IE hospitalizations increased ($1.58 billion in 2003 to $2.34 billion in 2016; P<.001). CONCLUSIONS: There is a substantial recent rise in endocarditis hospitalizations in the United States. Although the adjusted in-hospital mortality of endocarditis and the cost of admission decreased over time, the overall expenditure on in-hospital care for endocarditis increased.
Authors: Safi U Khan; Muhammad Zia Khan; Muhammad U Khan; Muhammad Shahzeb Khan; Mamas A Mamas; Muhammad Rashid; Ron Blankstein; Salim S Virani; Michelle C Johansen; Michael D Shapiro; Michael J Blaha; Miguel Cainzos-Achirica; Farhaan S Vahidy; Khurram Nasir Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2021-04-08
Authors: Joëlla W Adams; Alexandra Savinkina; James C Hudspeth; Mam Jarra Gai; Raagini Jawa; Laura R Marks; Benjamin P Linas; Alison Hill; Jason Flood; Simeon Kimmel; Joshua A Barocas Journal: JAMA Netw Open Date: 2022-02-01
Authors: Khawaja M Talha; Mark J Dayer; Martin H Thornhill; Wajeeha Tariq; Verda Arshad; Imad M Tleyjeh; Kent R Bailey; Raj Palraj; Nandan S Anavekar; M Rizwan Sohail; Daniel C DeSimone; Larry M Baddour Journal: Open Forum Infect Dis Date: 2021-09-25 Impact factor: 4.423
Authors: Farshad Amirkhosravi; Qasim Al Abri; Alexander J Lu; Lamees I El Nihum; Renee K Eng; Moritz C Wyler von Ballmoos; Mahesh K Ramchandani Journal: J Cardiothorac Surg Date: 2022-07-08 Impact factor: 1.522